Nautilus Biotechnology (NAUT) Assets (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Assets of $163.6 million for Q2 2026, down 7.99% sequentially from $177.8 million in Q1 2026, and down 23.27% YoY from $213.2 million in Q2 2025.
Nautilus Biotechnology (NAUT) Assets (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Assets for 7 years, with the latest figure at $163.6 million in Q2 2026.
- Quarterly Assets fell 23.27% year-over-year to $163.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $163.6 million (down 23.27% YoY) and the FY2025 annual result came in at $191.1 million, down 21.27% from the prior year.
- Assets eased to $163.6 million in Q2 2026 per NAUT's latest filing, from $177.8 million in the prior quarter.
- Over five years, Assets peaked at $384.7 million in Q1 2022 and troughed at $163.6 million in Q2 2026.
- A 5-year average of $278.0 million and a median of $280.7 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2026: Assets soared 155.6% in 2022, then declined 23.27% in 2026.
- Over 5 years, Assets stood at $350.1 million in 2022, then slipped by 12.71% to $305.6 million in 2023, then retreated by 20.56% to $242.7 million in 2024, then decreased by 21.27% to $191.1 million in 2025, then fell by 14.41% to $163.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $163.6 million, $177.8 million, and $191.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 163.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 163.58 Mn |
| Mar 31, 2026 | 177.78 Mn |
| Dec 31, 2025 | 191.11 Mn |
| Sep 30, 2025 | 200.92 Mn |
| Jun 30, 2025 | 213.19 Mn |
| Mar 31, 2025 | 227.69 Mn |
| Dec 31, 2024 | 242.74 Mn |
| Sep 30, 2024 | 259.70 Mn |
| Jun 30, 2024 | 272.75 Mn |
| Mar 31, 2024 | 288.65 Mn |
| Dec 31, 2023 | 305.57 Mn |
| Sep 30, 2023 | 318.34 Mn |
| Jun 30, 2023 | 330.77 Mn |
| Mar 31, 2023 | 345.88 Mn |
| Dec 31, 2022 | 350.05 Mn |
| Sep 30, 2022 | 359.31 Mn |
| Jun 30, 2022 | 371.71 Mn |
| Mar 31, 2022 | 384.67 Mn |
| Dec 31, 2021 | 398.45 Mn |
| Sep 30, 2021 | 385.35 Mn |